Overview

This trial is active, not recruiting.

Conditions ischemic attack, transient, stroke
Treatment drug use counselling
Sponsor Norwegian University of Science and Technology
Collaborator St. Olavs Hospital
Start date November 2012
End date September 2015
Trial size 300 participants
Trial identifier NCT02089074, 2012/1224a

Summary

Use of drugs is an important factor in secondary prophylaxis after transient ischemic attack (TIA), but studies show that adherence to the prescribed drugs is often poor. This randomised controlled trial aims to investigate whether a systematic follow up of drug treatment using medication reconciliation, medication reviews and patient counselling by clinical pharmacists, improves adherence and/or decreases cardiovascular events the first three months and the first year after TIA. Patient satisfaction will also be compared between the two groups.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Pharmacist conducting drug reconciliation, medication reviews and drug use counselling during hospitalisation. Follow up telephone calls 1 week, 1 month, 2 months and three months after discharge from hospital
drug use counselling
(No Intervention)
The patients in the control group receive no intervention just treatment and follow up according to national standards

Primary Outcomes

Measure
adherence to drug treatment in secondary prevention after TIA
time frame: 3 months

Secondary Outcomes

Measure
adherence to drug treatment in secondary prevention after TIA
time frame: 1 year
Persistence
time frame: 3 months
Incidence of stroke and cardiovascular events and deaths
time frame: 3 months
degree of disability or dependence in the daily activities
time frame: 3 months
patient satisfaction
time frame: 3 months
Persistence
time frame: 1 year
Incidence of stroke and cardiovascular events and deaths
time frame: 1 year
degree of disability or dependence in the daily activities
time frame: 1 year
patient satisfaction
time frame: 1 year

Eligibility Criteria

Male or female participants from 18 years up to 90 years old.

Inclusion Criteria: - Probable or possible transient ischemic attack - Residing in Central Norway - Examined within 2 weeks after the onset of symptoms - Modified Rankin Scale 3 or less and living at home - enrolled in the MIDNOR-TIA study NCT02038725 - Informed consent

Additional Information

Official title Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack: Adherence and Cardiovascular Events in the First Three Months
Trial information was received from ClinicalTrials.gov and was last updated in November 2015.
Information provided to ClinicalTrials.gov by Norwegian University of Science and Technology.